Brought to you by 
Amgen invests $25mm in Infinity with drug development deal
13 Jul 2006
Executive Summary
Infinity Pharmaceuticals (focuses on developing cancer therapeutics) licensed Amgen nonexclusive rights to its collection of small molecules, which it will use to identify potential therapeutic agents over a three-year period. In return, Amgen made a $25mm investment in the company for less than a 15% stake.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen invests $25mm in Infinity with drug development deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice